Wen‐Chien Chou

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska et al. · Journal of Clinical Oncology · 2012 · 1.2K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations

Jih‐Luh Tang, Hsin‐An Hou, Chien‐Yuan Chen et al. · Blood · 2009 · 345 citations · Full text

Medicine, Genetics, Molecular Genetics +17

TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics

Wen‐Chien Chou, Sheng‐Chieh Chou, Chieh‐Yu Liu et al. · Blood · 2011 · 323 citations · Full text

Life Sciences, Hematology, Oncology +14

DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications

Hsin‐An Hou, Yuan‐Yeh Kuo, Chieh‐Yu Liu et al. · Blood · 2011 · 239 citations · Full text

Medicine, Genetics, Molecular Genetics +15